Repligen Stock Price, News & Analysis

Repligen (NASDAQ:RGEN) has announced a strategic partnership with Novasign to enhance its bioprocessing digitalization capabilities. The collaboration involves integrating Novasign's machine learning and modeling workflow into Repligen's tangential flow filtration (TFF) systems.

As part of the agreement, Repligen will make an investment in Novasign to support its expansion. The partnership aims to leverage digital twins technology and AI-powered solutions to streamline process development, enable real-time predictive control, and reduce development timelines and costs in bioprocessing operations.

The integration will strengthen Repligen's Process Analytical Technology (PAT)-enabled systems and create opportunities for advanced AI modeling within Repligen platforms.

Repligen (NASDAQ:RGEN) reported strong Q2 2025 financial results with revenue reaching $182 million, marking a 15% year-over-year increase and 17% organic non-COVID growth. The company demonstrated robust performance with orders growing over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue.

Key financial metrics include GAAP net income of $15 million ($0.26 per share) and adjusted net income of $21 million ($0.37 per share). The company maintains a strong balance sheet with $709 million in cash and equivalents.

Based on strong execution and visibility, Repligen increased its full-year 2025 revenue guidance to $715-$735 million, representing 12.5-15.5% year-over-year non-COVID organic growth. The company launched ProConnex® MixOne and published its 2024 Sustainability report.

Repligen Corporation (NASDAQ:RGEN) has scheduled its second quarter 2025 financial results announcement for Tuesday, July 29, 2025. The company will release its earnings before market open and host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and six-month periods ended June 30, 2025.

Investors can access the conference call via phone at (800) 715-9871 (domestic) or (646) 307-1963 (international). A webcast will also be available through the company's Investor Relations website. Both the call and webcast will be archived for future access, with replay available at (800) 770-2030 (US) or (609) 800-9909 (international) using passcode 7706699.

Repligen Corporation (NASDAQ:RGEN) has published its 2024 Corporate Sustainability Report, titled "Perspectives on Progress". The report outlines the company's sustainability initiatives across six key areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways. Key achievements include expanding 100% renewable electricity usage to all 19 manufacturing sites, reducing waste generation by 25% and waste intensity by 32% year-over-year, and broadening Scope 3 emissions inventory. The report aligns with UN Sustainable Development Goals and reporting frameworks including GRI Standards and SASB. The company also completed the UNGC Network USA Business and Human Rights Accelerator program and opened a new Training and Innovation Center in Waltham, MA.

Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing technology company, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The event is scheduled for June 3-5 in Chicago. Olivier Loeillot, President and CEO, will deliver a company overview presentation on June 3rd at 1:20 p.m. CT. Investors can access the live webcast through Repligen's Investor Relations website, with a replay available for a limited time after the event.

Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in two major investor conferences in May 2025. The company's Chief Financial Officer, Jason K. Garland, will represent Repligen at:

1. RBC Capital Markets' 2025 Global Healthcare Conference in New York (May 20-21), featuring an analyst-led discussion on May 20 at 3:35 p.m. ET

2. Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis (May 28)

Both events will include one-on-one meetings with investors. The RBC conference presentation will be available via live webcast on Repligen's Investor Relations website.

Repligen reported strong Q1 2025 financial results with revenue reaching $169 million, marking a 10% year-over-year increase and 14% organic non-COVID growth. The company saw orders grow nearly 20% across all franchises.

Key highlights include:

• Biopharma and consumables revenue increased over 20% year-over-year
• Completed acquisition of 908 Devices' bioprocessing portfolio
• Launched CTech™ SoloVPE® Plus System for UV-based analysis
• Adjusted operating income up 72% year-over-year

Financial metrics show improvement with GAAP gross profit at $91 million and adjusted earnings per share of $0.39. The company maintains its 2025 guidance with expected revenue of $695M-$720M and organic growth of 9.5%-13.5%. Cash position remains strong at $697 million as of March 31, 2025.

Repligen (NASDAQ:RGEN) has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025. The company will release its earnings press release before market opening, followed by a conference call at 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2025.

The conference call will be accessible via toll-free numbers: (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. A webcast will also be available through the company's Investor Relations website. Replay options include dial-in numbers (877) 344-7529 (US), (855) 669-9658 (Canada), and (412) 317-0088 (international) with passcode 6386085.

Repligen (NASDAQ:RGEN) has appointed Jacob Johnson as Vice President of Investor Relations. Johnson, who previously served as Managing Director and Research Analyst at Stephens Inc., will lead investor relations and report to CFO Jason K. Garland.

Johnson brings significant experience in the life sciences tools and pharma services sector, having covered Repligen as a research analyst since 2019. He previously worked as a research associate on Stephens' healthcare services team and in investment management. Johnson holds a B.A. in Economics and Mathematics from Sewanee and an M.S. Finance from Washington University's Olin Business School.

He succeeds Sondra Newman, who is retiring after leading global investor relations and corporate communications since 2012.